Sor­ry No­vo: Sanofi wins Abl­ynx over with $4.8B buy­out bid, bag­ging nanobody plat­form tech

Sanofi $SNY has struck again — this time ac­quir­ing Abl­ynx, the Bel­gian biotech that has turned down two pre­vi­ous bids by No­vo Nordisk, for $4.8 bil­lion.

The French drug­mak­er agreed to pay a whop­ping $55.81 per share to swal­low Abl­ynx’s an­ti­body tech­nol­o­gy, al­most 50% high­er than No­vo’s $33.60 per share of­fer. In­vestors clear­ly liked how Abl­ynx held out, send­ing its shares $ABLX up 17% in pre­mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER